Trial Profile
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of RMJH-111b in Adult Subjects With Essential Hypertension
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Magnesium citrate (Primary)
- Indications Essential hypertension
- Focus Adverse reactions; Proof of concept
- 11 Nov 2019 Results presented in the RMJ Holdings media release.
- 16 Jul 2016 New trial record
- 13 Jul 2016 Status changed from recruiting to completed